{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T19:39:11Z","timestamp":1779219551209,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T00:00:00Z","timestamp":1642291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T00:00:00Z","timestamp":1642291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s12325-021-02022-z","type":"journal-article","created":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T08:05:31Z","timestamp":1642320331000},"page":"1247-1266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Management of Patients with Relapsed and\/or Refractory Multiple Myeloma Treated with Novel Combination Therapies in Routine Clinical Practice in Germany"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8580-3109","authenticated-orcid":false,"given":"H. Tilman","family":"Steinmetz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moushmi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Milce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Haidar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achim","family":"Rieth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Lebioda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rn","family":"Kohnke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,16]]},"reference":[{"issue":"10","key":"2022_CR1","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.3390\/cancers12102885","volume":"12","author":"A Bobin","year":"2020","unstructured":"Bobin A, Liuu E, Moya N, et al. Multiple myeloma: an overview of the current and novel therapeutic approaches in 2020. Cancers (Basel). 2020;12(10):2885. https:\/\/doi.org\/10.3390\/cancers12102885.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2022_CR2","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374\u2013403. https:\/\/doi.org\/10.1016\/j.ejca.2012.12.027.","journal-title":"Eur J Cancer"},{"key":"2022_CR3","volume-title":"Cancer in Germany in 2015\/2016","author":"Robert Koch Institute","year":"2020","unstructured":"Robert Koch Institute. Cancer in Germany in 2015\/2016. 12th ed. Berlin: Robert Koch Institute; 2020.","edition":"12"},{"issue":"1","key":"2022_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21\u201333. https:\/\/doi.org\/10.4065\/78.1.21.","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"2022_CR5","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.3390\/cancers12113488","volume":"12","author":"S Ninkovic","year":"2020","unstructured":"Ninkovic S, Quach H. Shaping the treatment paradigm based on the current understanding of the pathobiology of multiple myeloma: an overview. Cancers (Basel). 2020;12(11):3488. https:\/\/doi.org\/10.3390\/cancers12113488.","journal-title":"Cancers (Basel)"},{"issue":"15","key":"2022_CR6","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/jco.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412\u201320. https:\/\/doi.org\/10.1200\/jco.2005.04.242.","journal-title":"J Clin Oncol"},{"issue":"26","key":"2022_CR7","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/jco.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863\u20139. https:\/\/doi.org\/10.1200\/jco.2015.61.2267.","journal-title":"J Clin Oncol"},{"issue":"24","key":"2022_CR8","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955\u201362. https:\/\/doi.org\/10.1182\/blood-2016-01-631200.","journal-title":"Blood"},{"key":"2022_CR9","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv52\u201361. https:\/\/doi.org\/10.1093\/annonc\/mdx096.","journal-title":"Ann Oncol"},{"issue":"2","key":"2022_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000528","volume":"5","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5(2): e528. https:\/\/doi.org\/10.1097\/HS9.0000000000000528.","journal-title":"Hemasphere"},{"key":"2022_CR11","unstructured":"European Medicines Agency 2021. https:\/\/www.ema.europa.eu\/en. Accessed 28 Oct 2021."},{"issue":"9","key":"2022_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1159\/000509018","volume":"43","author":"HT Steinmetz","year":"2020","unstructured":"Steinmetz HT, Singh M, Lebioda A, et al. Patient characteristics and outcomes of relapsed\/refractory multiple myeloma in patients treated with proteasome inhibitors in Germany. Oncol Res Treat. 2020;43(9):449\u201359. https:\/\/doi.org\/10.1159\/000509018.","journal-title":"Oncol Res Treat"},{"issue":"7","key":"2022_CR13","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.clml.2018.04.007","volume":"18","author":"S Jagannath","year":"2018","unstructured":"Jagannath S, Abonour R, Durie BGM, et al. Heterogeneity of second-line treatment for patients with multiple myeloma in the Connect MM registry (2010\u20132016). Clin Lymphoma Myeloma Leuk. 2018;18(7):480\u20135. https:\/\/doi.org\/10.1016\/j.clml.2018.04.007.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2022_CR14","unstructured":"National Cancer Institute; 2020. The Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Myeloma. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed 28 Oct 2021."},{"issue":"2","key":"2022_CR15","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/j.clml.2020.10.002","volume":"21","author":"M Engelhardt","year":"2021","unstructured":"Engelhardt M, Ihorst G, Singh M, et al. Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany. Clin Lymphoma Myeloma Leuk. 2021;21(2):e160\u201375. https:\/\/doi.org\/10.1016\/j.clml.2020.10.002.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2022_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175(2):252\u201364. https:\/\/doi.org\/10.1111\/bjh.14213.","journal-title":"Br J Haematol"},{"issue":"9","key":"2022_CR17","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467\u201373. https:\/\/doi.org\/10.1038\/sj.leu.2404284.","journal-title":"Leukemia"},{"issue":"1","key":"2022_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/leu.2008.291","volume":"23","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3\u20139. https:\/\/doi.org\/10.1038\/leu.2008.291.","journal-title":"Leukemia"},{"issue":"1","key":"2022_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/13696998.2020.1867469","volume":"24","author":"TH Steinmetz","year":"2021","unstructured":"Steinmetz TH, Singh M, Lebioda A, et al. Healthcare resource utilization and costs among patients with relapsed and\/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany. J Med Econ. 2021;24(1):114\u201322. https:\/\/doi.org\/10.1080\/13696998.2020.1867469.","journal-title":"J Med Econ"},{"issue":"10","key":"2022_CR20","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1016\/j.clml.2018.06.018","volume":"18","author":"M Mohty","year":"2018","unstructured":"Mohty M, Terpos E, Mateos MV, et al. Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. Clin Lymphoma Myeloma Leuk. 2018;18(10):e401\u201319. https:\/\/doi.org\/10.1016\/j.clml.2018.06.018.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2022_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/bjh.14193","volume":"175","author":"MS Raab","year":"2016","unstructured":"Raab MS, Cavo M, Delforge M, et al. Multiple myeloma: practice patterns across Europe. Br J Haematol. 2016;175(1):66\u201376. https:\/\/doi.org\/10.1111\/bjh.14193.","journal-title":"Br J Haematol"},{"issue":"6","key":"2022_CR22","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00277-017-2991-0","volume":"96","author":"M Merz","year":"2017","unstructured":"Merz M, Kellermann L, Poenisch W, et al. Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey. Ann Hematol. 2017;96(6):987\u201393. https:\/\/doi.org\/10.1007\/s00277-017-2991-0.","journal-title":"Ann Hematol"},{"issue":"4","key":"2022_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000045","volume":"2","author":"SGR Verelst","year":"2018","unstructured":"Verelst SGR, Blommestein HM, De Groot S, et al. Long-term outcomes in patients with multiple myeloma: a retrospective analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS). Hemasphere. 2018;2(4): e45. https:\/\/doi.org\/10.1097\/hs9.0000000000000045.","journal-title":"Hemasphere"},{"issue":"1","key":"2022_CR24","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.clml.2018.08.019","volume":"19","author":"N Despi\u00e9gel","year":"2019","unstructured":"Despi\u00e9gel N, Touboul C, Flinois A, et al. Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France. Clin Lymphoma Myeloma Leuk. 2019;19(1):e13-28. https:\/\/doi.org\/10.1016\/j.clml.2018.08.019.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2022_CR25","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1182\/blood-2019-128030","volume":"134","author":"M Merz","year":"2019","unstructured":"Merz M, Patel V, Kutikova L, et al. Treatment patterns in patients (PTS) with refractory\/relapsed multiple myeloma (RRMM) in Germany between 2016 and 2018. Blood. 2019;134(suppl 1):4734. https:\/\/doi.org\/10.1182\/blood-2019-128030.","journal-title":"Blood"},{"issue":"1","key":"2022_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11096-020-01105-1","volume":"43","author":"J Chen","year":"2021","unstructured":"Chen J, Zhou L, Liu X, et al. Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis. Int J Clin Pharm. 2021;43(1):2\u201310. https:\/\/doi.org\/10.1007\/s11096-020-01105-1.","journal-title":"Int J Clin Pharm"},{"issue":"8","key":"2022_CR27","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.3390\/cancers12082113","volume":"12","author":"S Rasch","year":"2020","unstructured":"Rasch S, Lund T, Asmussen JT, et al. Multiple myeloma associated bone disease. Cancers (Basel). 2020;12(8):2113. https:\/\/doi.org\/10.3390\/cancers12082113.","journal-title":"Cancers (Basel)"},{"key":"2022_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2018.100215","volume":"14","author":"C Kim","year":"2019","unstructured":"Kim C, Bhatta S, Cyprien L, Fonseca R, Hernandez RK. Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: observations from real-world data. J Bone Oncol. 2019;14: 100215. https:\/\/doi.org\/10.1016\/j.jbo.2018.100215.","journal-title":"J Bone Oncol"},{"issue":"6","key":"2022_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.clml.2014.12.002","volume":"15","author":"RM Rifkin","year":"2015","unstructured":"Rifkin RM, Abonour R, Terebelo H, et al. Connect MM Registry: the importance of establishing baseline disease characteristics. Clin Lymphoma Myeloma Leuk. 2015;15(6):368\u201376. https:\/\/doi.org\/10.1016\/j.clml.2014.12.002.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2022_CR30","doi-asserted-by":"publisher","first-page":"238146831881425","DOI":"10.1177\/2381468318814253","volume":"4","author":"S Gonzalez-McQuire","year":"2019","unstructured":"Gonzalez-McQuire S, Dimopoulos MA, Weisel K, et al. Development of an initial conceptual model of multiple myeloma to support clinical and health economics decision making. MDM Policy Pract. 2019;4(1):2381468318814253. https:\/\/doi.org\/10.1177\/2381468318814253.","journal-title":"MDM Policy Pract"},{"issue":"1","key":"2022_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/ijlh.12882","volume":"41","author":"D Saxe","year":"2019","unstructured":"Saxe D, Seo EJ, Bergeron MB, Han JY. Recent advances in cytogenetic characterization of multiple myeloma. Int J Lab Hematol. 2019;41(1):5\u201314. https:\/\/doi.org\/10.1111\/ijlh.12882.","journal-title":"Int J Lab Hematol"},{"issue":"11","key":"2022_CR32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1159\/000321124","volume":"33","author":"W Knauf","year":"2010","unstructured":"Knauf W, Kellermann L, Poenisch W, et al. How to treat multiple myeloma\u2014a representative multicentre treatment survey. Onkologie. 2010;33(11):604\u201310. https:\/\/doi.org\/10.1159\/000321124.","journal-title":"Onkologie"},{"issue":"6","key":"2022_CR33","doi-asserted-by":"publisher","first-page":"5043","DOI":"10.3892\/ol.2016.5375","volume":"12","author":"TM Moehler","year":"2016","unstructured":"Moehler TM, Merz M, Kellermann L, Goldschmidt H, Knauf W. Diagnostic and therapeutic approaches to multiple myeloma patients: \u201creal-world\u201d data from representative multicentre treatment surveys in Germany between 2008 and 2011. Oncol Lett. 2016;12(6):5043\u201351. https:\/\/doi.org\/10.3892\/ol.2016.5375.","journal-title":"Oncol Lett"},{"key":"2022_CR34","doi-asserted-by":"publisher","first-page":"S497","DOI":"10.1016\/j.jval.2019.09.513","volume":"22","author":"A Oriol","year":"2019","unstructured":"Oriol A, Steinmetz T, Patel V, et al. Clinical and treatment characteristics of patients with relapsed\/refractory multiple myeloma (RRMM) in Europe. Value Health. 2019;22:S497\u20138. https:\/\/doi.org\/10.1016\/j.jval.2019.09.513.","journal-title":"Value Health"},{"key":"2022_CR35","doi-asserted-by":"publisher","first-page":"S923","DOI":"10.1016\/j.jval.2019.09.2740","volume":"22","author":"V Patel","year":"2019","unstructured":"Patel V, Kap EJ, Kutikova L. Treatment patterns in relapsed\/refractory multiple myeloma patients in Germany. Value Health. 2019;22:S923. https:\/\/doi.org\/10.1016\/j.jval.2019.09.2740.","journal-title":"Value Health"},{"issue":"5","key":"2022_CR36","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/bjh.15680","volume":"18","author":"MS Raab","year":"2019","unstructured":"Raab MS, Fink L, Schoen P, et al. Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016. Br J Haematol. 2019;18(5):981\u20134. https:\/\/doi.org\/10.1111\/bjh.15680.","journal-title":"Br J Haematol"},{"issue":"9","key":"2022_CR37","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/17474086.2020.1800451","volume":"13","author":"AS Bruno","year":"2020","unstructured":"Bruno AS, Willson JL, Opalinska JM, et al. Recent real-world treatment patterns and outcomes in US patients with relapsed\/refractory multiple myeloma. Expert Rev Hematol. 2020;13(9):1017\u201325. https:\/\/doi.org\/10.1080\/17474086.2020.1800451.","journal-title":"Expert Rev Hematol"},{"key":"2022_CR38","unstructured":"Chari A, Weisel KC, Usmani SZ, et al. Evolving treatment patterns in multiple myeloma (MM) differ by age and region: analysis from INSIGHT MM, a global, prospective, observational study. European Haematology Association 2019 congress abstract PF601. https:\/\/library.ehaweb.org\/eha\/2019\/24th\/266400\/ajai.chari.evolving.treatment.patterns.in.multiple.myeloma.%28mm%29.differ.by.age.html. Accessed 24 Nov 2021."},{"issue":"Suppl 1","key":"2022_CR39","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1182\/blood-2019-122706","volume":"134","author":"M Merz","year":"2019","unstructured":"Merz M, Vande Broek I, P\u00e9rez M, et al. Evolving treatment trends in relapsed\/refractory multiple myeloma (RRMM) in Europe from 2016 to 2018: analysis of a multi-national survey. Blood. 2019;134(Suppl 1):3115. https:\/\/doi.org\/10.1182\/blood-2019-122706.","journal-title":"Blood"},{"issue":"2","key":"2022_CR40","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/annonc\/mdt559","volume":"25","author":"E de Azambuja","year":"2014","unstructured":"de Azambuja E, Ameye L, Paesmans M, et al. The landscape of medical oncology in Europe by 2020. Ann Oncol. 2014;25(2):525\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdt559.","journal-title":"Ann Oncol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-02022-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-02022-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-02022-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T09:21:19Z","timestamp":1647076879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-02022-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,16]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["2022"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-02022-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,16]]},"assertion":[{"value":"30 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}